Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sorafenib exposure decreases over time in patients with hepatocellular carcinoma.
Arrondeau J, Mir O, Boudou-Rouquette P, Coriat R, Ropert S, Dumas G, Rodrigues MJ, Rousseau B, Blanchet B, Goldwasser F. Arrondeau J, et al. Among authors: blanchet b. Invest New Drugs. 2012 Oct;30(5):2046-9. doi: 10.1007/s10637-011-9764-8. Epub 2011 Oct 29. Invest New Drugs. 2012. PMID: 22038662
Drug interactions with solid tumour-targeted therapies.
Thomas-Schoemann A, Blanchet B, Bardin C, Noé G, Boudou-Rouquette P, Vidal M, Goldwasser F. Thomas-Schoemann A, et al. Among authors: blanchet b. Crit Rev Oncol Hematol. 2014 Jan;89(1):179-96. doi: 10.1016/j.critrevonc.2013.08.007. Epub 2013 Aug 28. Crit Rev Oncol Hematol. 2014. PMID: 24041628 Review.
Prevalence of drug-drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management.
Bellesoeur A, Gataa I, Jouinot A, Mershati SE, Piketty AC, Tlemsani C, Balakirouchenane D, Monribot A, Vidal M, Batista R, de Percin S, Villeminey C, Alexandre J, Goldwasser F, Blanchet B, Boudou-Rouquette P, Thomas-Schoemann A. Bellesoeur A, et al. Among authors: blanchet b. Cancer Chemother Pharmacol. 2021 Oct;88(4):741-751. doi: 10.1007/s00280-021-04311-4. Epub 2021 Jul 24. Cancer Chemother Pharmacol. 2021. PMID: 34304283
Toxicity of sorafenib: clinical and molecular aspects.
Blanchet B, Billemont B, Barete S, Garrigue H, Cabanes L, Coriat R, Francès C, Knebelmann B, Goldwasser F. Blanchet B, et al. Expert Opin Drug Saf. 2010 Mar;9(2):275-87. doi: 10.1517/14740330903510608. Expert Opin Drug Saf. 2010. PMID: 20078249 Review.
Saturable absorption of sorafenib in patients with solid tumors: a population model.
Hornecker M, Blanchet B, Billemont B, Sassi H, Ropert S, Taieb F, Mir O, Abbas H, Harcouet L, Coriat R, Dauphin A, Goldwasser F, Tod M. Hornecker M, et al. Among authors: blanchet b. Invest New Drugs. 2012 Oct;30(5):1991-2000. doi: 10.1007/s10637-011-9760-z. Epub 2011 Oct 18. Invest New Drugs. 2012. PMID: 22006162 Clinical Trial.
153 results